Aptissen’s strategy is to build a robust pipeline of locally administered therapies and oral food supplements to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA).
The information contained on this page reflects Aptissen’s clinical development program as of 30 June, 2021, and is not intended for promotional purposes. There can be no guarantee that any clinical development program reaches completion or that any indication or investigational therapy receives regulatory approval.
